1 August 2007 in Journal of Neurotrauma
High intracranial pressure (HICP) may be a very early event after traumatic brain injury (TBI), but in most cases, especially when contusions and edema develop over time, HICP will worsen over succeeding days. This study describes the incidence and severity of elevated intracranial pressure (ICP) after TBI and attempts to document its time course. In this prospective study, 201 TBI patients in whom ICP was monitored for more than 12 h were evaluated. ICP was measured, digitalized, and analyzed after manual filtering. The number of episodes of HICP and the mean ICP value for every 12-h interval were calculated. When monitoring was concluded, the highest mean ICP collected in every patient was identified. A total of 21,000 h of ICP monitoring were recorded. Active treatment to prevent or reduce HICP was used in 200 patients. HICP was documented in 155 cases. Half of the patients had their highest mean ICP during the first 3 days after injury, but many showed delayed ICP elevation, with 25% showing highest mean ICP after day 5. In these cases, HICP was significantly worse and required more intense therapies.
6 April 2011 in Journal of Cerebral Blood Flow & Metabolism
We investigated the occurrence of endotoxin (lipopolysaccharide, LPS) preconditioning in traumatic brain injury (TBI), evaluating the time window of LPS-induced protection, its persistence, and the associated molecular mechanisms. Mice received 0.1 mg/kg LPS or saline intraperitoneally and subsequently TBI (by controlled cortical impact brain injury) at various time intervals. Mice receiving LPS 3, 5, or 7 days before TBI showed attenuated motor deficits at 1 week after injury compared with mice receiving saline. Those receiving LPS 5 days before injury had also a reduced contusion volume (7.9 ± 1.3 versus 12 ± 2.3 mm3) and decreased cell death. One month after injury, the protective effect of LPS on contusion volume (14.5 ± 1.2 versus 18.2 ± 1.2 mm3) and neurologic function was still present. Traumatic brain injury increased glial fibrillary acidic protein, CD11b, CD68, tumor necrosis factor-α, interleukin (IL)-10, and IL-6 mRNA expression 24 hours after injury. Lipopolysaccharide administered 5 (but not 9) days before injury increased the expression of CD11b (233%) and of interferon β (500%) in uninjured mice, while it reduced the expression of CD68 (by 46%) and increased that of IL-6 (by 52%) in injured mice. Lipopolysaccharide preconditioning conferred a long-lasting neuroprotection after TBI, which was associated with a modulation of microglia/macrophages activity and cytokine production.
1 June 2016 in Journal of Neurotrauma
An impaired ability to regulate microglia activation by fractalkine (CX3CL1) leads to microglia chronic sub-activation. How this condition affects outcome after acute brain injury is still debated with studies showing contrasting results depending on the timing and the brain pathology. Here we investigated the early and delayed consequences of CX3CR1 (fractalkine receptor) deletion on neurological outcome, and on the phenotypical features of the myeloid cells present in the lesion of traumatic brain injured (TBI) mice. Wild type (WT) and CX3CR1-/- C57Bl/6 mice were subjected to sham or controlled cortical impact brain injury. Outcome was assessed at 4d and 5w after TBI by neuroscore, neuronal count and TUNEL staining. Compared to WT, CX3CR1-/- TBI mice showed a significant reduction of sensorimotor deficits and lower cellular damage in the injured cortex 4d post-TBI. Conversely, at 5w they showed a worsening of sensorimotor deficits and pericontusional neuronal death. Microglia (M) and macrophage (μ) activation and polarization were assessed by quantitative immunohistochemistry for CD11b, CD68, Ym1 and iNOS, markers of M/μ activation, phagocytosis, M2 and M1 phenotypes, respectively. Morphological analysis revealed a decreased area and perimeter of CD11b+ cells in CX3CR1-/- mice at 4d post-TBI, whereas, at 5w, both parameters were significantly higher compared to WT mice. At 4d CX3CR1-/- mice showed significantly decreased CD68 and iNOS immunoreactivity while, at 5w post-injury, they showed a selective increase of iNOS. Gene expression on CD11b+ sorted cells revealed an increase of IL10 and IGF1 at 1d and a decrease of IGF1 4d and 5w post-TBI, in CX3CR1-/- compared to WT mice. These data show an early protection followed by a chronic exacerbation of TBI outcome in the absence of CX3CR1. Thus, longitudinal effects of myeloid cell manipulation at different stages of pathology should be investigated to understand how and when their modulation may offer therapeutic chances.
1 February 2009 in Critical Care Medicine
The aim of the study was to evaluate the effects of C1-inhibitor (C1-INH), an endogenous inhibitor of complement and kinin systems, on neurobehavioral and histological outcome following controlled cortical impact brain injury. Experimental prospective randomized study in mice. Experimental laboratory. Male C57Bl/6 mice (n = 81). Mice were subjected to controlled cortical impact brain injury followed by an intravenous bolus of either C1-INH (15 U either at 10 minutes or 1 hour postinjury) or saline (equal volume, 150 microl at 10 minutes postinjury). Sham-operated mice received identical surgery and saline injection without brain injury. Neurological motor function was evaluated weekly for 4 weeks using the Composite Neuroscore. Cognitive function was evaluated at 4 weeks postinjury using the Morris Water Maze. Histological outcome was performed by measuring the contusion volume at 1 week and 4 weeks postinjury. Brain-injured mice receiving C1-INH at 10 minutes postinjury showed attenuated motor deficits, cognitive dysfunction and reduced contusion volume compared to brain-injured mice receiving saline. Mice receiving C1-INH at 1 hour postinjury showed reduced motor deficits compared to brain-injured mice receiving saline, but no significantly different cognitive and histological outcome. Immunohistochemical analysis showed that 20 minutes after infusion, C1-INH was localised on endothelial cells and in brain tissue surrounding brain capillaries of the injured hemisphere. Our results show that post-traumatic administration of C1-INH attenuates neuro-behavioral deficits and histological damage associated with traumatic brain injury.
24 April 2013 in Journal of Cerebral Blood Flow & Metabolism
The role of tumor necrosis factor (TNF) and its receptors after traumatic brain injury (TBI) remains unclear. We evaluated the effects of genetic deletion of either p55 or p75 TNF receptor on neurobehavioral outcome, histopathology, DNA damage and apoptosis-related cell death/survival gene expression (bcl-2/bax), and microglia/macrophage (M/M) activation in wild-type (WT) and knockout mice after TBI. Injured p55 (– / –) mice showed a significant attenuation while p75 (– / –) mice showed a significant worsening of sensorimotor deficits compared with WT mice over 4 weeks postinjury. At the same time point, contusion volume in p55 (– / –) mice (11.1 ± 3.3 mm3) was significantly reduced compared with WT (19.7 ± 3.4 mm3) and p75 (– / –) mice (20.9 ± 3.2 mm3). At 4 hours postinjury, bcl-2/bax ratio mRNA expression was increased in p55 (– / –) compared with p75 (– / –) mice and was associated with reduced DNA damage terminal deoxynucleotidyl transferaseYmediated dUTP nick end labeling (TUNEL-positivity), reduced CD11b expression and increased Ym1 expression at 24 hours postinjury in p55 (– / –) compared with p75 (– / –) mice, indicative of a protective M/M response. These data suggest that TNF may exacerbate neurobehavioral deficits and tissue damage via p55 TNF receptor whose inhibition may represent a specific therapeutic target after TBI.